Free Trial

Kamada (NASDAQ:KMDA) Research Coverage Started at StockNews.com

Kamada logo with Medical background

Research analysts at StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA - Get Free Report) in a research note issued on Wednesday. The firm set a "buy" rating on the biotechnology company's stock.

Separately, HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Kamada in a report on Thursday, May 9th.

Get Our Latest Research Report on KMDA

Kamada Stock Down 2.1 %

NASDAQ:KMDA traded down $0.11 during midday trading on Wednesday, reaching $5.06. The stock had a trading volume of 6,389 shares, compared to its average volume of 14,731. Kamada has a 12-month low of $4.08 and a 12-month high of $6.53. The firm has a fifty day simple moving average of $5.29 and a two-hundred day simple moving average of $5.66. The stock has a market cap of $290.85 million, a P/E ratio of 22.00 and a beta of 1.06.

Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.02). Kamada had a net margin of 8.33% and a return on equity of 5.50%. The business had revenue of $37.74 million during the quarter, compared to analyst estimates of $38.01 million. On average, sell-side analysts anticipate that Kamada will post 0.26 earnings per share for the current fiscal year.


Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. EWA LLC acquired a new position in shares of Kamada during the 4th quarter worth $68,000. Calton & Associates Inc. acquired a new position in Kamada in the 4th quarter valued at about $111,000. Y.D. More Investments Ltd raised its stake in Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company's stock valued at $177,000 after purchasing an additional 15,000 shares during the last quarter. Aristides Capital LLC raised its stake in Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company's stock valued at $347,000 after purchasing an additional 16,635 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company's stock valued at $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company's stock.

About Kamada

(Get Free Report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Further Reading

Should you invest $1,000 in Kamada right now?

Before you consider Kamada, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.

While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines